Aurobindo Pharma announced that the company's wholly owned subsidiary, Auro Vaccines has entered into a license agreement with Hilleman Laboratories Singapore to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.
Auro Vaccines will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate.
Powered by Capital Market - Live News